New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a [...]
Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete [...]
MIDDLETON, WI., July 19, 2023 - An international consortium led by the Americas Committee for Treatment and Research in Multiple [...]
The MS+ community has lost its 'grandfather.' Barry GW Arnason, MD, FAAN. He is generally regarded as one of (if not, the) founder of [...]
Abstracts for CMSC 2023 Annual Meeting Reflect Latest Multidisciplinary Multiple Sclerosis Research The 37th Annual Meeting of the [...]
CMSC 2023 Annual Meeting Program Offers Cutting-Edge Science and Clinical Skill Updates for MS Care Professionals CMSC (Consortium of [...]
